Eastern Spanish experience with nivolumab in metastatic renal cell carcinoma
ConclusionBenefit/risk profile of nivolumab in Eastern-Spanish real-world population with mRCC after tyrosine-kinase inhibitors was consistent with prior real-life studies reported as well as pivotal study.
Source: Clinical and Translational Oncology - Category: Cancer & Oncology Source Type: research
More News: Biochemistry | Brain | Brain Cancers | Cancer | Cancer & Oncology | Cancer Therapy | Carcinoma | Hepatocellular Carcinoma | Hypothyroidism | Kidney Cancer | Liver | Liver Cancer | Nephrectomy | Nephritis | Neurology | Renal Cell Carcinoma | Smokers | Spain Health | Study | Toxicology | Urology & Nephrology